M. Dietlein et al., Radioiodine therapy and thyroid-associated orbitopathy: risk factors and preventive effects of glucocorticoids, EXP CL E D, 107, 1999, pp. S190-S194
Citations number
23
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
Whether or not thyroid-associated orbitopathy is exacerbated by radioiodine
therapy is a matter of controversy. Several risk factors can be listed: pr
e-existing active ophthalmopathy, hypothyroidism following radioiodine ther
apy, elevated T3 levels during radioiodine therapy, recurrent or persisting
hyperthyroidism after low-dose radioiodine therapy and smoking. Recent stu
dies and own data demonstrate that worsening of pre-existing thyroid-associ
ated orbitopathy after radioiodine therapy can be prevented by the administ
ration of glucocorticoids. Even in patients without evident ophthalmopathy
the prophylactic use of glucocorticoids is in our opinion justified to mini
mize a small but known risk of the development of ocular symptoms. Larger p
rospective randomized studies are needed to establish the optimal dose and
duration of the required anti-inflammatory therapy.